Clinical Efficacy and Safety of Oral Qing-Dai in Patients with Ulcerative Colitis - Clinical Efficacy and Safety of Oral Qing-Dai in Patients with Ulcerative Colitis

Kumamoto red cross hospital division of gatroenterology0 个研究点目标入组 20 人开始时间: 2016年12月3日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•colitis associated dysplasia, symptomatic intestinal stenosis a history of side effect or allergy of Chinese herbal medicine a need for potential surgery after enrollment in this study signs of other types of colitis, severe liver ,heart or renal diseases; or a history of malignant diseases, psychosomatic disorders,infectious disease. Pregnant or breastfeeding women. The patients treated with leukocyte aphaeresis,prednisolone >=40mg,adalimumab,tacrolimus or cyclosporine within 2 weeks before the commencement of the study. The patients treated with infliximab whitin 4 weeks before the commencement of the study. Changing the dose of mesalamine or prednisolone within 2 weeks before the commencement of the study. The patients treated with thiopurine within 12 weeks before the commencement of the study. Changing the dose of thiopurine within 4weeks before the commencement of the study.

发起方

Kumamoto red cross hospital division of gatroenterology